Lineage Cell Therapeutics
LCTX
69 hedge funds and large institutions have $152M invested in Lineage Cell Therapeutics in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 4 closing their positions.
439% more call options, than puts
Call options by funds: $2.58M | Put options by funds: $478K
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
33% more capital invested
Capital invested by funds: $114M → $152M (+$38M)
17% more funds holding
Funds holding: 59 → 69 (+10)
0.07% more ownership
Funds ownership: 45.47% → 45.54% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
CQS Cayman
Camana Bay, Grand Cayman,
Cayman Islands
|
+$589K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$348K |
| 3 |
FM
Family Management
New York
|
+$279K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$219K |
| 5 |
State Street
Boston,
Massachusetts
|
+$219K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
-$2.22M |
| 2 |
Morgan Stanley
New York
|
-$283K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$159K |
| 4 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
-$73K |
| 5 |
Bank of New York Mellon
New York
|
-$48.6K |
LCTX Hedge Fund Activity: Q1 2015 in Review
69 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2015, worth a combined $152M — up 33% from $114M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new LCTX positions and 4 closed out — a net gain of 10 holders — while 22 added to existing stakes and 12 trimmed.
The largest buyer was CQS Cayman, opening a new position worth an estimated $589K. The largest seller was Destination Wealth Management, exiting entirely with an estimated $2.22M sold.
- 69 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2015, up from 59 in Q4 2014.
- Funds reported $152M of Lineage Cell Therapeutics stock for Q1 2015, up 33% quarter-over-quarter.
- 14 funds opened new Lineage Cell Therapeutics positions in Q1 2015 and 4 closed out, a net change of +10 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2015 was CQS Cayman, an estimated $589K added.
- The largest Lineage Cell Therapeutics seller in Q1 2015 was Destination Wealth Management, an estimated $2.22M sold.
Based on aggregated 13F filings for Q1 2015.